Search Results for " Eslicarbazepine acetate "
Eslicarbazepine acetate Related Products
SynZeal is a leading innovator in pharmaceutical reference standards. We supply high-quality Reference Standards of Eslicarbazepine acetate, pharmacopeial and non-pharmacopeial Eslicarbazepine acetate impurities, metabolites, stable isotope products, and nitrosamines (N-NO products). Eslicarbazepine acetate impurities reference standards are useful in pharmaceutical research. They are useful in product development, ANDA and DMF filing, quality control (QC), method validation, and stability studies. It is also useful in the identification of unknown impurities and the assessment of genotoxic potential.
Eslicarbazepine acetate-related products are thoroughly characterized. Eslicarbazepine acetate products are supplied with detailed COA & analytical data meeting regulatory compliance. We can also provide EP/USP traceable standards based on your requirements. The supplied products are re-tested at regular intervals.
- SZ目录编号: SZ-E034001
- CAS 号: 236395-14-5
- 分子式: C17H16N2O3
- 分子量: 296.3
- 投资状态: In Stock
- SZ目录编号: SZ-E034011
- CAS 号: 186694-45-1
- 分子式: C17H16N2O3
- 分子量: 296.3
- 投资状态: In Stock
Eslicarbazepine Acetate Chiral Peak Id Mixuture
- SZ目录编号: SZ-E034012
- CAS 号: NA
- 分子式: C15H12N2O2 : 2(C17H16N2O3)
- 分子量: 845.0
- 投资状态: Limited Stock
- SZ目录编号: SZ-E034013
- CAS 号: 952740-36-2
- 分子式: C18H18N2O3
- 分子量: 310.4
- 投资状态: Custom Synthesis
10,11-Dihydro-10-hydroxy Carbamazepine-D4
- SZ目录编号: SZ-E034D01
- CAS 号: 1020719-39-4
- 分子式: C15H10D4N2O2
- 分子量: 258.3
- 投资状态: Custom Synthesis
- SZ目录编号: SZ-E034D04
- CAS 号: NA
- 分子式: C15H11D3N2O2
- 分子量: 257.3
- 投资状态: Custom Synthesis
Eslicarbazepine D8 Acetate (racemate)
- SZ目录编号: SZ-E034D02
- CAS 号: NA
- 分子式: C17H8D8N2O3
- 分子量: 304.4
- 投资状态: Custom Synthesis
- Rel. CAS No: : 236395-14-5 (Unlabeled)
- SZ目录编号: SZ-E034D03
- CAS 号: 1261393-17-2
- 分子式: C15H6D8N2O2
- 分子量: 262.3
- 投资状态: Custom Synthesis
Eslicarbazepine Acetate Nitroso Impurity 1
- SZ目录编号: SZ-E034014
- CAS 号: NA
- 分子式: C16H14N2O3
- 分子量: 282.3
- 投资状态: Custom Synthesis